Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
Total: 27 #1
TickerYPF [NYSE]
CompanyYPF Sociedad Anonima
IndustryOil & Gas Integrated
Market Cap5.27BEPS (ttm)0.53
P/E12.48EPS this Y100.40%
Forward P/E3.10EPS next Y-29.65%
PEG-EPS past 5Y15.00%
P/S0.51EPS next 5Y-6.39%
P/B0.38EPS Q/Q-
Dividend-Sales Q/Q65.30%
Insider Own99.50%Inst Own47.70%
Insider Trans0.00%Inst Trans62.20%
Short Float5.01%Earnings-
Analyst Recom3.70Target Price4.35
Avg Volume2.35M52W Range2.82 - 6.64
Sep-08-22 09:00AMIs Most-Watched Stock YPF Sociedad Anonima (YPF) Worth Betting on Now? Zacks
Aug-31-22 08:50AMHere Is Why Bargain Hunters Would Love Fast-paced Mover YPF Sociedad Anonima (YPF) Zacks
Aug-30-22 09:15AMYPF Sociedad Anonima (YPF) Soars to 52-Week High, Time to Cash Out? Zacks
Aug-24-22 12:00PMHere's Why YPF Sociedad Anonima (YPF) is a Great Momentum Stock to Buy Zacks
Aug-22-22 06:03AMBeat the Market the Zacks Way: Dillard's (DDS), Sotherly Hotels (SOHO), Casey's (CASY) in Focus Zacks
Aug-15-22 09:49AMBest Value Stocks to Buy for August 15th Zacks
Aug-15-22 08:50AMWhy Fast-paced Mover YPF Sociedad Anonima (YPF) Is a Great Choice for Value Investors Zacks
Aug-15-22 08:20AMNew Strong Buy Stocks for August 15th Zacks
Jul-26-22 05:50PMYPF Sociedad Anonima (YPF) Gains As Market Dips: What You Should Know Zacks
Jul-22-22 06:00PMYPF Sociedad Anonima (YPF) Flat As Market Sinks: What You Should Know Zacks
YPF Sociedad Anonima, an energy company, engages in the oil and gas upstream and downstream activities in Argentina. The company's upstream operations include the exploration, development, and production of crude oil, natural gas, and NGLs. Its downstream operations include the refining, marketing, transportation, and distribution of oil, petroleum products, petroleum derivatives, petrochemicals, LPG, and bio-fuels, as well as in gas separation, natural gas distribution operations, and power generation. As of December 31, 2021, it had interests in 119 oil and gas fields; approximately 643 million barrels (mmbbl) of oil; and approximately 2,447 billion cubic feet (bcf) of gas. It also had a retail distribution network of 1,654 YPF-branded service stations; and 18 exploration permits. In addition, the company owns and operates three refineries with combined annual refining capacity of approximately 120 mmbbl; approximately 2,800 kilometers of crude oil pipelines with approximately 640,000 barrels of aggregate daily transportation capacity of refined products; and crude oil tankage of approximately 7 mmbbl, as well as maintains terminal facilities at five Argentine ports. Further, it participates in 21 power generation plants with an aggregate installed capacity of 3,091 megawatts; offers diesel, fertilizers, lubricants, phytosanitary products, and ensiling bags; and supplies diesel, gasoline, fuel oil, coal, asphalts, paraffin, and sulfur, CO2, decanted oil, and aromatic extract. The company was founded in 1977 and is headquartered in Buenos Aires, Argentina.
CompanyCatalyst Pharmaceuticals, Inc.
Market Cap1.55BEPS (ttm)0.50
P/E29.68EPS this Y-48.10%
Forward P/E17.54EPS next Y20.80%
PEG-EPS past 5Y29.80%
P/S9.12EPS next 5Y-
P/B6.33EPS Q/Q75.00%
Dividend-Sales Q/Q45.90%
Insider Own7.30%Inst Own76.30%
Insider Trans-9.90%Inst Trans7.05%
Short Float7.15%EarningsAug 09/a
Analyst Recom2.00Target Price16.90
Avg Volume2.13M52W Range4.81 - 15.07
Sep-05-22 01:46PMCatalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Is Going Strong: Is the Market Following Fundamentals? Simply Wall St.
Aug-26-22 12:45PM3 Reasons Why Catalyst (CPRX) Is a Great Growth Stock Zacks
Aug-26-22 12:00PMHere's Why Catalyst Pharmaceutical (CPRX) is a Great Momentum Stock to Buy Zacks
Aug-26-22 09:40AMHas Aerie Pharmaceuticals (AERI) Outpaced Other Medical Stocks This Year? Zacks
Aug-26-22 08:30AMIf You Invested $1000 in Catalyst Pharmaceutical 10 Years Ago, This Is How Much You'd Have Now Zacks
Aug-24-22 08:03AMCatalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference GlobeNewswire
Aug-23-22 10:53AMGot $2,500? These 2 Small-Cap Monsters Are Crushing Tesla Stock Motley Fool
Aug-09-22 06:35PMCatalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates Zacks
Aug-09-22 04:25PMCatalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update GlobeNewswire
Jul-26-22 08:03AMCatalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022 GlobeNewswire
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRANDE ALICIAVP, Treasurer and CFOAug 29Sale14.2057,000809,560407,442Aug 30 05:00 PM
GRANDE ALICIAVP, Treasurer and CFOAug 26Sale14.4011,095159,768464,442Aug 30 05:00 PM
Daly Richard JDirectorAug 24Option Exercise2.5340,000101,20092,666Aug 26 05:01 PM
Tierney David SDirectorAug 22Option Exercise2.5320,00050,600328,207Aug 23 05:01 PM
Tierney David SDirectorAug 22Sale14.1620,000283,180308,207Aug 23 05:01 PM
CompanyFirst Solar, Inc.
Market Cap14.53BEPS (ttm)1.76
P/E76.37EPS this Y17.40%
Forward P/E61.83EPS next Y2422.20%
PEG13.54EPS past 5Y25.30%
P/S5.86EPS next 5Y5.64%
P/B2.44EPS Q/Q-32.50%
Dividend-Sales Q/Q-1.30%
Insider Own0.30%Inst Own82.20%
Insider Trans-17.82%Inst Trans2.85%
Short Float4.91%EarningsJul 28/a
Analyst Recom2.70Target Price120.57
Avg Volume2.43M52W Range59.60 - 135.20
Sep-08-22Upgrade Goldman Sell → Buy $60 → $172
Sep-08-22 05:50AM3 Stocks to Buy If They Take a Dip Motley Fool
Sep-08-22 03:51AMGameStop, Asana, First Solar Rise Premarket; American Eagle Outfitters Falls Investing.com
Sep-07-22 06:42PMWhy First Solar Stock Climbed Today Motley Fool
Sep-04-22 05:16PMWhy First Solar Stock Rocketed More Than 28% in August Motley Fool
Sep-01-22 11:31AMWhy Is SunPower (SPWR) Up 7.9% Since Last Earnings Report? Zacks
Sep-01-22 09:56AMBiden praises U.S. investments by Micron, First Solar, Toyota, others: 'A direct result of my economic plan' MarketWatch
Sep-01-22 08:59AMThese 10 Renewable Energy Stocks Can Benefit as Europe Braces for Harsh Winter Insider Monkey
Aug-31-22 10:35AMFirst Solar Stock in 3 Minutes Motley Fool
Aug-31-22 09:44AMFirst Solar to Invest $1 Billion in New U.S. Factory Investopedia
Aug-31-22 08:52AMFirst Solar (FSLR) to Invest $1.2B to Boost Production Capacity Zacks
First Solar, Inc. provides photovoltaic (PV) solar energy solutions in the United State, Japan, France, Canada, India, Australia, and internationally. The company designs, manufactures, and sells cadmium telluride solar modules that converts sunlight into electricity. It serves developers and operators of systems, utilities, independent power producers, commercial and industrial companies, and other system owners. The company was formerly known as First Solar Holdings, Inc. and changed its name to First Solar, Inc. in 2006. First Solar, Inc. was founded in 1999 and is headquartered in Tempe, Arizona.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gloeckler MarkusChief Technology OfficerAug 18Sale118.7446555,2141,373Aug 19 04:03 PM
Gloeckler MarkusChief Technology OfficerAug 17Option Exercise0.0084402,217Aug 19 04:03 PM
Gloeckler MarkusChief Technology OfficerAug 17Sale115.1447855,0371,373Aug 19 04:03 PM
KENNEDY R CRAIGDirectorAug 15Sale117.4160070,44619,785Aug 17 04:27 PM
ANTOUN GEORGESChief Commercial OfficerAug 05Buy100.539,946999,87137,300Aug 05 06:04 PM
CompanyPROCEPT BioRobotics Corporation
IndustryMedical Devices
Market Cap2.00BEPS (ttm)-1.56
P/E-EPS this Y-9.30%
Forward P/E-EPS next Y22.00%
PEG-EPS past 5Y-
P/S40.27EPS next 5Y52.70%
P/B8.31EPS Q/Q33.20%
Dividend-Sales Q/Q6.40%
Insider Own3.30%Inst Own80.70%
Insider Trans-46.30%Inst Trans9.92%
Short Float5.80%EarningsAug 04/a
Analyst Recom2.00Target Price47.71
Avg Volume449.63K52W Range15.38 - 47.73
Aug-22-22 04:03PMPROCEPT BioRobotics Corp. to Present at 2022 Wells Fargo Healthcare Conference GlobeNewswire
Aug-05-22 05:30PMPROCEPT BioRobotics Corporation (PRCT) Q2 2022 Earnings Call Transcript Motley Fool
Aug-04-22 04:03PMPROCEPT BioRobotics Reports Second Quarter 2022 Financial Results and Increases 2022 Revenue Guidance GlobeNewswire
Jul-14-22 04:02PMPROCEPT BioRobotics to Report Second Quarter 2022 Financial Results on August 4, 2022 GlobeNewswire
Jul-10-22 08:32AMInsiders of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) received good value on their investment after their US$11m purchase jumped US$3.3m in value Simply Wall St.
Jun-16-22 02:30PMProcept Biorobotics Corp Joins Elite Club Of Stocks With RS Ratings Over 90 Investor's Business Daily
Jun-09-22 09:01AMHow Much Of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Do Insiders Own? Simply Wall St.
Jun-09-22 08:00AMPROCEPT BioRobotics Corporation Announces Additional Positive Coverage Policies Regarding Aquablation Therapy for Men with Enlarged Prostates GlobeNewswire
May-10-22 06:20AMNeed To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues Simply Wall St.
May-05-22 04:02PMPROCEPT BioRobotics Reports First Quarter 2022 Financial Results and Increases 2022 Revenue Guidance GlobeNewswire
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Krummel Thomas MDirectorJun 22Option Exercise4.512,68912,134102,920Jun 22 07:11 PM
Krummel Thomas MDirectorJun 21Option Exercise2.5917,31144,773100,231Jun 22 07:11 PM
Krummel Thomas MDirectorJun 21Sale35.9820,000719,65382,920Jun 22 07:11 PM
Nouri AlalehEVP, CLO, CORP. SEC.May 16Sale35.0667823,77146,468May 16 05:49 PM
VIKING GLOBAL INVESTORS LP10% OwnerMar 18Sale29.901,249,00037,345,100298,205Mar 22 08:51 PM
CompanyAlaunos Therapeutics, Inc.
Market Cap771.87MEPS (ttm)-0.25
P/E-EPS this Y3.70%
Forward P/E-EPS next Y-13.60%
PEG-EPS past 5Y22.60%
P/S1929.67EPS next 5Y-
P/B18.11EPS Q/Q56.30%
Dividend-Sales Q/Q-
Insider Own1.10%Inst Own40.90%
Insider Trans0.00%Inst Trans-23.07%
Short Float15.02%EarningsAug 15/b
Analyst Recom2.30Target Price3.80
Avg Volume3.16M52W Range0.41 - 3.50
Sep-07-22 08:30AMAlaunos Therapeutics to Participate in Upcoming Investor Conferences in September GlobeNewswire
Sep-06-22 08:00AMAlaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy GlobeNewswire
Aug-24-22 03:00PMAlaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference GlobeNewswire
Aug-15-22 07:00AMAlaunos Therapeutics Reports Second Quarter 2022 Financial Results GlobeNewswire
Aug-08-22 08:50AMAlaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022 GlobeNewswire
Aug-04-22 05:00PMAlaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations GlobeNewswire
Jul-06-22 09:31AMThinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? PR Newswire
Jun-30-22 07:07AMIs Alaunos Therapeutics (NASDAQ:TCRT) Using Debt In A Risky Way? Simply Wall St.
Jun-27-22 08:00AMAlaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025 GlobeNewswire
Jun-01-22 08:30AMAlaunos Therapeutics to Present at the Jefferies Healthcare Conference GlobeNewswire
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
CompanyADMA Biologics, Inc.
Market Cap524.44MEPS (ttm)-0.42
P/E-EPS this Y41.60%
Forward P/E-EPS next Y39.40%
PEG-EPS past 5Y20.40%
P/S4.76EPS next 5Y-
P/B4.81EPS Q/Q52.80%
Dividend-Sales Q/Q90.40%
Insider Own2.10%Inst Own74.70%
Insider Trans0.00%Inst Trans11.78%
Short Float16.09%EarningsAug 10/a
Analyst Recom1.70Target Price4.67
Avg Volume2.71M52W Range1.01 - 2.85
Aug-31-22 04:55PMTop Penny Stocks for September 2022 Investopedia
Aug-11-22 06:08PMWhy ADMA Biologics Stock Triumphed on Thursday Motley Fool
Aug-10-22 05:25PMAdma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates Zacks
Aug-10-22 04:05PMADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update GlobeNewswire
Aug-10-22 07:16AMADMA Biologics, Inc. (NASDAQ:ADMA) insiders placed bullish bets worth US$580k in the last 12 months Simply Wall St.
Aug-08-22 10:00AMAnalysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for Zacks
Aug-03-22 10:00AMAdma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Aug-03-22 07:00AMADMA Biologics to Report Second Quarter 2022 Financial Results on August 10, 2022 GlobeNewswire
Jun-26-22 09:11AMShareholders in ADMA Biologics (NASDAQ:ADMA) have lost 50%, as stock drops 12% this past week Simply Wall St.
Jun-21-22 07:00AMADMA Biologics Announces Addition to the Russell 2000® Index GlobeNewswire
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grossman Adam SPresident and CEOOct 25Buy1.00250,000250,0001,128,444Oct 26 07:00 AM
Grossman Adam SPresident and CEOOct 25Buy1.00100,000100,0002,137,616Oct 26 07:00 AM
LENZ BRIANEVP, CFOOct 25Buy1.0030,00030,0001,065,501Oct 26 07:00 AM
Grossman Jerrold BDirectorOct 25Buy1.00100,000100,000260,864Oct 26 07:00 AM
KWON YOUNGDirectorOct 25Buy1.00100,000100,000200,000Oct 26 07:00 AM
TickerBJ [NYSE]
CompanyBJ's Wholesale Club Holdings, Inc.
IndustryDiscount Stores
Market Cap10.63BEPS (ttm)3.56
P/E21.81EPS this Y1.90%
Forward P/E19.80EPS next Y9.23%
PEG3.36EPS past 5Y54.30%
P/S0.58EPS next 5Y6.50%
P/B12.21EPS Q/Q28.60%
Dividend-Sales Q/Q22.20%
Insider Own0.80%Inst Own-
Insider Trans-14.52%Inst Trans-2.50%
Short Float3.46%EarningsAug 18/b
Analyst Recom2.30Target Price82.81
Avg Volume2.14M52W Range51.45 - 77.77
Sep-08-22 07:55AMThe Zacks Analyst Blog Highlights Marriott Vacations Worldwide, Marriott International, BJ's Wholesale Club Holdings, JAKKS Pacific and Enthusiast Gaming Holdings Zacks
Sep-08-22 06:30AMBJs Wholesale Club Reveals its List of Top 10 Toys for the Holiday Season Business Wire
Sep-07-22 12:45PMLooking for a Growth Stock? 3 Reasons Why BJ's (BJ) is a Solid Choice Zacks
Sep-07-22 09:40AMIs BJ's Wholesale Club (BJ) Stock Outpacing Its Consumer Discretionary Peers This Year? Zacks
Sep-07-22 08:16AM5 Big Winners From a Sharp Rise in Consumer Confidence Zacks
Sep-07-22 06:05AM2 Winning Stocks to Buy No Matter What the Market Is Doing Motley Fool
Sep-06-22 02:16PMYour Favorite Wholesale Club Is Steamrolling the Market Zacks
Sep-05-22 07:46AMColumbia Sportswear (COLM) Down More Than 10% in 3 Months Zacks
Sep-02-22 09:36AMPrestige Consumer (PBH) Brands & E-commerce Strength Bode Well Zacks
Sep-01-22 10:10AMCostcos August Sales Were Up Again. Membership Fees Could Rise Too. Barrons.com
BJ's Wholesale Club Holdings, Inc., together with its subsidiaries, operates warehouse clubs on the east coast of the United States. It provides perishable, general merchandise, gasoline, and other ancillary services. The company sells its products through the websites BJs.com, BerkleyJensen.com, Wellsleyfarms.com, and Delivery.bjs.com as well as the mobile app. As of June 10, 2022, it operated 229 warehouse clubs and 160 gas locations in 17 states. The company was formerly known as Beacon Holding Inc. and changed its name to BJ's Wholesale Club Holdings, Inc. in February 2018. BJ's Wholesale Club Holdings, Inc. was founded in 1984 and is headquartered in Westborough, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Eddy Robert W.President & CEOSep 07Sale76.7612,738977,752207,754Sep 07 08:11 PM
Eddy Robert W.President & CEOSep 06Sale75.041,10482,844220,492Sep 07 08:11 PM
Eddy Robert W.President & CEOSep 02Sale75.162,800210,448221,596Sep 07 08:11 PM
Luce GrahamSVP, SecretaryAug 31Option Exercise26.445,942157,12134,128Sep 02 04:17 PM
Luce GrahamSVP, SecretaryAug 31Sale74.569,896737,84624,232Sep 02 04:17 PM
TickerAES [NYSE, S&P 500]
CompanyThe AES Corporation
IndustryUtilities - Diversified
Market Cap17.95BEPS (ttm)-0.74
P/E-EPS this Y5.90%
Forward P/E15.40EPS next Y9.29%
PEG-EPS past 5Y4.38%
P/S1.53EPS next 5Y8.00%
P/B8.41EPS Q/Q-848.10%
Dividend2.33%Sales Q/Q14.00%
Insider Own0.30%Inst Own97.50%
Insider Trans-0.96%Inst Trans1.98%
Short Float1.37%EarningsAug 04/a
Analyst Recom1.80Target Price28.75
Avg Volume5.43M52W Range18.62 - 27.21
Sep-07-22 05:03PMHeat wave, record energy demand puts California in fossil-fuel conundrum MarketWatch
Sep-07-22 11:30AMWhy Is Dominion Energy (D) Down 1.1% Since Last Earnings Report? Zacks
Sep-07-22 03:44AMMong Duong Finance Holdings BV -- Moody's upgrades Mong Duong Finance's senior secured rating to Ba2; changes outlook to stable Moody's
Sep-07-22 03:37AMMong Duong Finance Holdings BV -- Moody's upgrades Mong Duong Finance's senior secured rating to Ba2; changes outlook to stable Moody's
Sep-01-22 09:55AMShould You Buy AES (AES) After Golden Cross? Zacks
Aug-29-22 06:20AMIs Invesco S&P 500 Equal Weight Utilities ETF (RYU) a Strong ETF Right Now? Zacks
Aug-25-22 01:18PMNorthern States Power Company (Wisconsin) -- Moody's announces completion of a periodic review for a group of North American Utilities issuers Moody's
Aug-16-22 07:14AMIs Now An Opportune Moment To Examine The AES Corporation (NYSE:AES)? Simply Wall St.
Aug-12-22 05:49PM6 Stocks to Play the Push for Renewable Energy Barrons.com
Aug-12-22 02:00AM6 Stocks to Play the Push for Renewable Energy Barrons.com
The AES Corporation operates as a diversified power generation and utility company. It owns and/or operates power plants to generate and sell power to customers, such as utilities, industrial users, and other intermediaries. The company also owns and/or operates utilities to generate or purchase, distribute, transmit, and sell electricity to end-user customers in the residential, commercial, industrial, and governmental sectors; and generates and sells electricity on the wholesale market. It uses a range of fuels and technologies to generate electricity, including coal, gas, hydro, wind, solar, and biomass; and renewables, such as energy storage and landfill gas. The company owns and/or operates a generation portfolio of approximately 31,459 megawatts. It has operations in the United States, Puerto Rico, El Salvador, Chile, Colombia, Argentina, Brazil, Mexico, Central America, the Caribbean, Europe, and Asia. The company was formerly known as Applied Energy Services, Inc. and changed its name to The AES Corporation in April 2000. The AES Corporation was incorporated in 1981 and is headquartered in Arlington, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLER JAMES HDirectorJun 01Option Exercise14.2619,280274,93319,280Jun 03 04:22 PM
MILLER JAMES HDirectorJun 01Sale21.6819,280418,0730Jun 03 04:22 PM
Coughlin StephenEVP and CFOMar 04Buy21.3047,0001,001,10067,622Mar 07 07:50 AM
Gluski AndresPresident and CEOJan 05Option Exercise11.17524,5115,858,7881,668,235Jan 07 04:17 PM
Gluski AndresPresident and CEOJan 05Sale23.78524,51112,474,2271,143,724Jan 07 04:17 PM
TickerENPH [NASD, S&P 500]
CompanyEnphase Energy, Inc.
Market Cap43.27BEPS (ttm)1.42
P/E223.07EPS this Y7.80%
Forward P/E63.48EPS next Y21.95%
PEG6.92EPS past 5Y22.50%
P/S24.93EPS next 5Y32.23%
P/B94.70EPS Q/Q92.60%
Dividend-Sales Q/Q67.70%
Insider Own1.20%Inst Own76.30%
Insider Trans-18.70%Inst Trans3.58%
Short Float3.57%EarningsJul 26/a
Analyst Recom2.00Target Price277.58
Avg Volume3.27M52W Range113.40 - 318.22
Sep-08-22 08:05AMDow Jones Futures: Market Rebounds, But Big Test Looms; 5 Hot Solar Plays Investor's Business Daily
Sep-08-22 08:01AMTop-Ranked Solar Stock Shines Light On New Buy Point Investor's Business Daily
Sep-07-22 04:32PMSolar ETF Invesco, IBD's Stock Of The Day, Heavily Weighted On Being Green Investor's Business Daily
Sep-07-22 09:05AMEnphase (ENPH) Extends Distribution Alliance With BayWa r.e. Zacks
Sep-07-22 08:30AMLet's Shine a Light on a Few Potential Solar Energy Trades TheStreet.com
Sep-07-22 08:03AMDow Jones Futures: Nasdaq Extends Losing Streak; Apple iPhone 14 On Call Investor's Business Daily
Sep-06-22 02:28PMEnphase Stock Is Rising. The Solar Firm Expanded a Partnership. Barrons.com
Sep-06-22 12:45PMEnphase Energy (ENPH) is an Incredible Growth Stock: 3 Reasons Why Zacks
Sep-06-22 08:08AMDow Jones Futures Rise; Energy Prices Lower Despite Surprise OPEC+ Move, Russia News Investor's Business Daily
Sep-06-22 08:00AMEnphase Energy and BayWa r.e. Expand Distribution Partnership in Europe GlobeNewswire
Enphase Energy, Inc., together with its subsidiaries, designs, develops, manufactures, and sells home energy solutions for the solar photovoltaic industry in the United States and internationally. The company offers semiconductor-based microinverter, which converts energy at the individual solar module level, and combines with its proprietary networking and software technologies to provide energy monitoring and control services. It also offers AC battery storage systems; Envoy communications gateway; and Enlighten cloud-based monitoring service, as well as other accessories. The company sells its solutions to solar distributors; and directly to large installers, original equipment manufacturers, strategic partners, and homeowners, as well as through its legacy product upgrade program or online store. Enphase Energy, Inc. was incorporated in 2006 and is headquartered in Fremont, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yang MandyVP, Chief Financial OfficerAug 10Sale292.961,687494,216107,149Aug 11 05:32 PM
RANHOFF DAVID AEVP & Chief Commercial OfficerAug 10Sale293.035,3691,573,30192,902Aug 11 05:34 PM
MORA RICHARDDirectorAug 02Sale297.332,825839,9641,600Aug 04 05:27 PM
GOMO STEVEN JDirectorJul 28Sale279.2135,82210,001,85441,456Jul 29 05:43 PM
Kortlang Benjamin JohnDirectorJul 28Sale268.5950,00013,429,419202,828Jul 29 05:39 PM
CompanySarepta Therapeutics, Inc.
Market Cap9.95BEPS (ttm)-5.87
P/E-EPS this Y27.50%
Forward P/E-EPS next Y23.50%
PEG-EPS past 5Y1.30%
P/S11.91EPS next 5Y-
P/B13.60EPS Q/Q-159.10%
Dividend-Sales Q/Q42.30%
Insider Own3.80%Inst Own83.60%
Insider Trans1.40%Inst Trans0.19%
Short Float8.18%EarningsAug 02/a
Analyst Recom1.90Target Price128.21
Avg Volume972.92K52W Range61.28 - 116.91
Sep-07-22 10:08AMClinical Hold on Sarepta's (SRPT) DMD Candidate Lifted by FDA Zacks
Sep-07-22 08:30AMSarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year GlobeNewswire
Sep-06-22 09:27AMFDA Lifts Clinical Hold On Sarepta's Dose-Expansion Part Of Duchenne Trial Benzinga
Sep-06-22 08:45AMSarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference GlobeNewswire
Sep-06-22 08:30AMSarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
Sep-02-22 11:31AMMirati (MRTX) Up 5.3% Since Last Earnings Report: Can It Continue? Zacks
Sep-01-22 11:31AMWhy Is Sarepta Therapeutics (SRPT) Up 13.8% Since Last Earnings Report? Zacks
Aug-31-22 05:59PMSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-30-22 01:47PM15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome Investor's Business Daily
Aug-29-22 10:23AM3 Biotech Stocks You Can Buy and Hold for the Next Decade Motley Fool
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chambers Michael AndrewDirectorAug 19Buy108.2846,1704,999,23051,078Aug 22 08:30 AM
BEHRENS M KATHLEENDirectorDec 15Option Exercise10.085,00050,400135,517Dec 16 08:00 PM
GRAY MARY ANNDirectorDec 10Option Exercise0.0096709,403Dec 14 08:02 PM
Rodino-Klapac LouiseHead of R&D, CSONov 24Buy79.333,780299,86765,678Nov 29 08:00 AM
INGRAM DOUGLAS SPresident & CEONov 17Buy79.9425,0262,000,578365,082Nov 17 06:24 PM